Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide.

Détails

Ressource 1Télécharger: 29085670_BIB_E1C5C73B9B4E.pdf (864.59 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_E1C5C73B9B4E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide.
Périodique
International journal of retina and vitreous
Auteur(s)
Abramson D.H., Shields C.L., Jabbour P., Teixeira L.F., Fonseca JRF, Marques MCP, Munier F.L., Puccinelli F., Hadjistilianou T., Bracco S., Chantada G., Ceciliano A., Gobin Y.P.
ISSN
2056-9920 (Print)
ISSN-L
2056-9920
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
3
Pages
40
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Ophthalmic artery chemosurgery [OAC, intra-arterial chemotherapy (IAC)] was introduced in 2006 as treatment modality for intraocular retinoblastoma. The purpose of this commentary is to retrospectively review the incidence of metastatic deaths in retinoblastoma patients treated with OAC worldwide over a 10 year period. Retrospective data regarding metastatic deaths was collected from six international retinoblastoma centers (New York City USA, Philadelphia USA, Sao Paulo Brazil, Siena Italy, Lausanne Switzerland and Buenos Aires Argentina). All retinoblastoma patients from these centers (naive and recurrent, unilateral and bilateral) treated with OAC/IAC since 2006 have been included in this study. Data regarding number of patients, number of OAC/IAC infusions, number unilateral and bilateral, number treated for naive disease or salvage and number of metastatic deaths have been assessed. Over a 10-year period of time 1139 patients received OAC/IAC for 4396 infusions. At last follow-up there were only three metastatic deaths (all treated in Buenos Aires).
The current survey assessed the recorded risk of metastatic deaths in six retinoblastoma centers worldwide in children with retinoblastoma (unilateral or bilateral) treated with OAC/IAC as primary or secondary therapy. Overall, the observed risk for metastatic deaths from retinoblastoma was <1% in OAC/IAC treated children.

Mots-clé
Intra-arterial (intrarterial) chemotherapy (IAC), Melphalan, Metastatic death, Ophthalmic artery chemosurgery (OAC), Retinoblastoma (Rb)
Pubmed
Open Access
Oui
Création de la notice
09/11/2017 17:45
Dernière modification de la notice
20/08/2019 16:05
Données d'usage